

R<sup>2</sup> is lower alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,

A is an alkylene, an alkenylene, or an alkynylene group spacer[,], [and]

*C<sup>1</sup>*  
Z designates dialkylcarbamoyl or lower alkyl, and

m is zero or 1 [.] ;

*Cout'd*  
Q is a sugar, a monophosphorylated sugar, or a polyphosphorylated sugar, [and phosphoryl-sugar group transporter recognition moiety adapted to enhance] which enhances the transport of polar compounds via the [Blood] blood brain barrier, through cell membranes, through kidney tubuli, [and] or through the gastrointestinal wall,

which Q entity can be optionally substituted or coupled to a physiologically active acceptable moiety,

and where X is an anion.

*C<sup>2</sup>*  
16 30. (Amended) The compound of claim 16, wherein polysaccharides are covalently coupled to [the PYR-hycrocarbyl] moiety A or attached by a physical interaction.

*C<sup>3</sup>*  
21 35. (Amended) [Use of a pharmaceutical composition according to claim 31, in the treatment of] A method of treating Alzheimer disease, tardive dyskinesia, effects of stroke, neuralgic pains and general analgesic effect[.], comprising administering to a subject in need thereof an effective amount

C<sup>3</sup>  
cont'd  
of a composition according to claim 31, thereby treating said subject.

C<sup>4</sup>  
23 ~~31~~. (Amended) [Use of a pharmaceutical composition according to claim ~~36~~<sup>22</sup>, for the treatment of, and alleviation of] A method of treating, and alleviating symptoms of, peripheral cholinergic disorders, glaucoma, myasthenia gravis, [treatment of] treating urine bladder dome, neurogenic urine bladder, hypercholinergic impairments, intoxication caused by reversible and irreversible cholinesterase, and for [the pretreatment of] pretreating organophosphorous intoxication[.], comprising administering to a subject in need thereof an effective amount of a composition according to claim 36, thereby alleviating the symptoms of said subject.

C<sup>5</sup>  
26 ~~40~~. (Amended) [Use of a pharmaceutical composition according to claim 38 for the delivery of] A method of delivering carbamates to the peripheral and central nervous system[.], comprising the step of administering to a subject in need thereof an effective amount of a composition according to claim ~~38~~<sup>24</sup>, thereby delivering a carbamate to the peripheral or central nervous system.--

REMARKS

claims 15-40 are pending in the instant application. Applicants have amended claims 15, 30, 35, 37 and 40. The